KDR and hepatocellular carcinoma: Based on the results of the REFLECT study, which approved lenvatinib (anti-VEGFR mAb) as a first-line treatment for advanced HCC patients [91], an open-label multicenter single-arm phase Ib study (NCT03006926) evaluated the efficacy of the combination of lenvatinib (anti-VEGFR mAb) with pembrolizumab (anti-PD-1 mAb) in unresectable HCC.